Vivian Iida Avelino‐silva - Infectious Diseases

Author Information

Vivian Iida Avelino-Silva is affiliated with the Department of Infectious and Parasitic Diseases at the Faculdade de Medicina da Universidade de São Paulo, as well as the Instituto de Medicina Tropical at the same university in São Paulo, Brazil. Her research primarily focuses on infectious diseases, with a particular emphasis on public health challenges in Latin America.

Research Contributions

Vivian Iida Avelino-Silva has made significant contributions to the field of infectious diseases. Her recent work includes studies on the genotype-specific features of South American yellow fever virus strains, the treatment of severe COVID-19 cases, and the ethical considerations surrounding the off-label use of drugs and COVID-19 vaccines. She has also investigated the safety and immunogenicity of the CoronaVac vaccine in people living with HIV and explored the predictors of knowledge and access to biomedical prevention among MSM and transgender men in Latin America. Her research addresses critical issues such as inequities in vaccination and mortality rates among indigenous populations in Brazil and the impact of COVID-19 on healthcare access and income.

Aliases

Vivian Iida Avelino-Silva is known by several aliases in academic publications, including Vivian I. Avelino-Silva, Vivian Avelino-Silva, and V. I. Avelino-Silva. These variations may appear in different contexts or collaborations.

Publication and Citation Metrics

Metric	Value
Total Papers	89
Citation Count	905
h-index	17

Publications:

Genotype-specific features reduce the susceptibility of South American yellow fever virus strains to vaccine-induced antibodies

DOI: 10.1016/j.chom.2021.12.009

Year: 2022

Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma versus standard of care: A multicenter Bayesian randomized open-label clinical trial (COOP-COVID-19-MCTI)

DOI: 10.1016/j.lana.2022.100216

Year: 2022

Assessment of novel technologies in healthcare - off-label use of drugs and the ethics of implementation and distribution of COVID-19 vaccines

DOI: 10.31744/einstein_journal/2021ED6840

Year: 2022

Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study

DOI: 10.1016/S2352-3018(22)00033-9

Year: 2022

Predictors of knowledge of and access to biomedical prevention among MSM and transgender men in Latin America: Results from the Latin American internet survey.

DOI: 10.1111/hiv.13238

Year: 2022

Clinical outcomes of HIV-syphilis coinfection among patients with no neurological symptoms: a retrospective cohort study.

DOI: 10.1111/hiv.13306

Year: 2022

Inequities in Vaccination and Mortality Rates Among Indigenous Populations Compared to the General Population in Brazil: A Time Series Analysis

DOI: 10.2139/ssrn.4071503

Year: 2022

COVID‐19 is not over and age is not enough: Using frailty for prognostication in hospitalized patients

DOI: 10.1111/jgs.17146

Year: 2021

Impact of COVID-19 on income, prevention attitudes, and access to healthcare among male clients in a Sexually Transmitted Infections clinic

DOI: 10.1016/j.bjid.2021.101617

Year: 2021

591The “Big 6”: A purpose-based framework for motivating and teaching epidemiologic methods

DOI: 10.1093/ije/dyab168.045

Year: 2021

What are Sporozoites?

How is Efficacy Measured?

How Can Lyme Disease be Prevented?

How Do Anopheles Mosquitoes Transmit Malaria?

How Does Ventilation Impact the Spread of Infectious Diseases?

How Do Epidemiologists Track Infectious Diseases?

What Are the Challenges in Infectious Disease Epidemiology?

How to Choose the Right Antimalarial Drug?

How Can Individuals Support CDC's Efforts?

What is One Health?

Partnered Content Networks

Relevant Topics